FFRct vs EchoGo Amyloidosis
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 60/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
Tool A (FFRct) is designed for diagnosing coronary artery disease by analyzing CCTA scans to assess blood flow in coronary arteries. In contrast, Tool B (EchoGo Amyloidosis) focuses on the early detection of cardiac amyloidosis through AI-powered analysis of echocardiogram video clips. While both are cardiology AI tools, their distinct target conditions and input modalities make them suitable for different diagnostic pathways.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
HeartFlow FFRct Analysis is a non-invasive AI-powered diagnostic tool that creates personalized 3D models of coronary arteries from CCTA scans to assess blood flow and aid in diagnosing coronary artery disease (CAD). Ultromics' EchoGou00ae Amyloidosis is the first FDA-cleared AI-powered screening tool that analyzes echocardiogram video clips to aid in the early detection of cardiac amyloidosis (CA).
FFRct Analysis utilizes data from CCTA (Coronary CT Angiography) scans to generate its 3D models and blood flow analysis. EchoGou00ae Amyloidosis analyzes echocardiogram video clips to identify suspected cardiac amyloidosis.
HeartFlow FFRct Analysis is cloud-based, deploying via the HeartFlow Network, AWS Cloud, or Virtual Private Cloud, with a local Virtual Appliance for data transfer. EchoGou00ae Amyloidosis is a cloud-based SaaS model designed for seamless integration with existing clinical workflows and IT infrastructure, including PACS, DICOM, and HL7.
FFRct Analysis generates personalized 3D digital models of coronary arteries and analyzes blood flow to identify areas of narrowing (FFRct values), aiding in diagnosing CAD and guiding treatment strategies. EchoGou00ae Amyloidosis provides a diagnostic output of 'suggestive' or 'not suggestive' of cardiac amyloidosis based on AI-powered analysis of echocardiographic markers, demonstrating high diagnostic accuracy (85% sensitivity, 93% specificity).
For FFRct Analysis, the CMS payment rate is $1,017 (2025), with commercial payer rates varying, and it has a Category I CPT code (75580). For EchoGou00ae Amyloidosis, inpatient analyses are covered by an NTAP Code (ICD-10 XXE2X19) for $1,000 (Medicare-covered), and outpatient analyses use HCPCS Code C9786 (Clinical APC Code 574) for $285, covered by Medicare and select commercial insurers.